Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer

Journal of Cancer Survivorship

Volumn 9, Issue 1, 2015, Pages 1-10

  Jones, Desiree ^a   Zhao, Fengmin ^b   Brell, Joanna ^c   Lewis, Mark A ^a   Loprinzi, Charles L ^d   Weiss, Matthias ^e   Fisch, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e MARSHFIELD CLINIC   (United States)

Author keywords

Colorectal cancer; Neuropathic pain; Neuropathy; Numbness tingling; Quality of life

Indexed keywords

FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; ONCOLOGY; OUTPATIENT; PAIN; PATHOLOGY; PSYCHOLOGY; QUALITY OF LIFE; SURVIVOR;

FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; PAIN; QUALITY OF LIFE; SURVIVORS;

EID: 84931956176     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-014-0379-x     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.
2. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. doi:10.1056/NEJMoa032709.
3. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(19):3109–16. doi:10.1200/jco.2008.20.6771.
4. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32(1):51–60. doi:10.1002/mus.20340.
5. Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med. 2010;13(11):1389–91. doi:10.1089/jpm.2010.0124.
6. Weickhardt A, Wells K, Messersmith W. Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol. 2011;2011:201593. doi:10.1155/2011/201593.
7. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438–44. doi:10.1002/cncr.27732.
8. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2012;20(11):2959–67. doi:10.1007/s00520-012-1428-5.
9. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2013;21(12):3307–13. doi:10.1007/s00520-013-1905-5.
10. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(21):2699–707. doi:10.1200/jco.2013.49.1514.
11. Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171–8. doi:10.1002/cncr.27489.
12. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(11):1472–8. doi:10.1200/jco.2010.33.0308.
13. Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013. doi:10.1200/jop.2012.000863.
14. Lewis MA, Zhao F, Jones D, Loprinzi C, Brell JM, Weiss M, Fisch MJ (2014) Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal versus breast, lung or prostate cancer—results from a prospective mulitcenter study. Support Care Cancer, Under review
15. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46.
16. Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manag. 2005;29(3):224–37. doi:10.1016/j.jpainsymman.2004.05.008.
17. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61(2):277–84.
18. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP. 2009.
19. Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJ, Mantyh P, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J (Sudbury, Mass). 2007;13(6):399–403. doi:10.1097/PPO.0b013e31815a999b.
20. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–10.
21. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA: J Am Med Assoc. 2013;309(13):1359–67. doi:10.1001/jama.2013.2813.
22. Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutrition (Edinburgh, Scotland). 2013;32(6):888–93. doi:10.1016/j.clnu.2013.04.007.
23. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/alliance). J Clin Oncol: Off J Am Soc Clin Oncol. 2013. doi:10.1200/jco.2013.52.0536.
24. Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Netherlands J Med. 2012;70(1):18–25.
25. Schroder S, Beckmann K, Franconi G, Meyer-Hamme G, Friedemann T, Greten HJ, et al. Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evidence-based Complement Alternat Med: eCAM. 2013;2013:423713. doi:10.1155/2013/423713.
26. Seretny M, Colvin L, Fallon M. Therapy for chemotherapy-induced peripheral neuropathy. JAMA: J Am Med Assoc. 2013;310(5):537–8. doi:10.1001/jama.2013.7902.
27. Smith EM, Pang H. Therapy for chemotherapy-induced peripheral neuropathy—in reply. JAMA: J Am Med Assoc. 2013;310(5):538. doi:10.1001/jama.2013.7905.
28. Postma TJ, Reijneveld JC, Heimans JJ. Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment? Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2013;24(6):1424–6. doi:10.1093/annonc/mdt173.
29. Schroeder S, Meyer-Hamme G, Epplée S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30(1):4–7. doi:10.1136/acupmed-2011-010034.
30. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2013. doi:10.1007/s00520-013-2075-1.